Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Professor of Oncology
University of Hamburg
Department of Oncology
Asklepios Tumorzentrum Hamburg
Department of Gastrointestinal Medical Oncology
Co-director for Clinical Research
Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas MD Anderson Cancer Center
Senior Clinical Editor
Associate Director, Scientific Services
Senior Director, Global Medical Education, Europe
Senior Director, Educational Strategy
This program is intended for medical oncologists and other healthcare providers who care for patients with pancreatic cancer globally.
This program has been made available online.
Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options
Latest data and expert guidance on targeting KRASG12C for treatment of solid tumors from Clinical Care Options (CCO)
Latest data and expert guidance on targeting KRASG12C for treatment of solid tumors in an online activity and a downloadable slideset from Clinical Care Options (CCO)
From Clinical Care Options (CCO), on-demand video featuring global experts on using PARP inhibitors for pancreatic cancer with BRCA1/2 mutations